Clinical trials: Next Generation Sequencing (NGS), open to volunteers
NSCLC
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
This multicenter, retrospective cohort study plans to enroll patients with lung adenocarcinoma who received neoadjuvant immunotherapy prior to surgery and did not achieve pathological complete response (non-pCR) upon…
- Trial name
- NCT07179445
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Plasma Cell Disorder
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand.
- Trial name
- genetics MM (NCT06330896)
- Volunteers
- 498 people
- Sponsor
- Siriraj Hospital
Rare Diseases, Genetic Predisposition to Disease
Genetic Causes of Discrepant Clinic in Monogenic Twins
In the DISCO-TWIN study (prospective, open-label molecular-genetic study), twin pairs with one healthy and one affected twin with molecularly undiagnosed diseases will be analysed by means of omics technologies and/ or…
- Trial name
- DISCO-TWIN (NCT04046796)
- Testing
- NGS Diagnostic
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Tuebingen
Hepatocellular Carcinoma, Colorectal Cancer
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumors.
- Trial name
- PDO (NCT06077591)
- Testing
- Patient-Derived Tumor Organoids
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Solid Tumor Malignancies, Metastatic Cancer
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid…
- Conditions
- Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- PROGRESS (NCT06896162)
- Testing
- Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NSCLC, NSCLC Stage IV
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
Lung cancer is the most common primary cancer of the lung and is responsible for the ever increasing number of cancer-related deaths worldwide.
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC, Recurrent
- Trial name
- NCT05701787
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
ALK-positive Advanced NSCLC Patients, Primary Resistance
Primary Resistance Mechanisms of ALK TKIs
Anaplastic lymphoma kinase (ALK) gene rearrangement is a known oncogenic driver in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have been clearly shown to produce excellent therapeutic effects and…
- Conditions
- ALK-positive Advanced NSCLC Patients, Primary Resistance, NGS
- Trial name
- NCT07045610
- Testing
- re-biopsy tumor with primary ALK tKI resistance for NGS
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)
- Trial name
- NCT06763302
- Testing
- Blinatumomab
- Volunteers
- 1,220 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Small Cell Lung Cancer
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker…
- Trial name
- NCT05257551
- Testing
- Observation
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Tempus AI
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Infertility, Implantation Rate
Hyaluronan-enriched Medium and Euploid Blastocyst Transfers
It has been proposed that enriching transfer media with hyaluronan (EmbryoGlue medium) improves pregnancy outcomes compared with media containing lower concentrations of this molecule.
- Conditions
- Infertility, Implantation Rate, Clinical Pregnancy Rate, Live Birth Rate
- Trial name
- GluePloid (NCT06165367)
- Testing
- EmbryoGlue Medium
- Where
- United Arab Emirates
- Volunteers
- 783 people, healthy volunteers welcome
- Sponsor
- ART Fertility Clinics LLC
B-All, Acute Lymphoblastic Leukemia
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL.
- Trial name
- NCT05621291
- Testing
- NGS testing
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Melanocytic Nevi, Melanoma (Skin Cancer)
Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions
This observational, prospective cohort study aims to evaluate the diagnostic relevance of Reflectance Confocal Microscopy (RCM) features in atypical melanocytic lesions scheduled for surgical excision, and to correlate these…
- Conditions
- Melanocytic Nevi, Melanoma (Skin Cancer), Next Generation Sequencing (NGS)
- Trial name
- NCT07277920
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Modena and Reggio Emilia
Rare Tumour
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug…
- Trial name
- SPRING (NCT06692491)
- Testing
- Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- Peking University Shenzhen Hospital
Classical Hodgkin Lymphoma
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (cHL) accounts for 15% of all cases of cancer in children and adolescents and represents the first cause of cancer during adolescence.
- Trial name
- EURHOLY (NCT07356882)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies.
- Trial name
- NCT03058588
- Testing
- Analysis with molecular biology
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of…
- Trial name
- LOLA-PROJECT (NCT06997458)
- Testing
- xF Tempus assay
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental